Condition
Overweight
Obesity
Locations
United States
Start date
22/09/2026
Identifiers
Trial ID NN9490-8027,
NCT number NCT07668414,
Eudract number Not Available
NCT number NCT07668414,
Eudract number Not Available
Summary
The purpose of this study is to find out if zenagamtide is safe and effective for treating participants who have excess body weight compared to treatment with semaglutide.
Trial Overview:
Treatment
DRUG: Zenagamtide
DRUG: Semaglutide
DRUG: Placebo (matched to semaglutide)
DRUG: Placebo (matched to zenagamtide)
Study type
INTERVENTIONAL
Trial duration
Sep 22 2026 - Oct 10 2028
Participants
650
Phase
III
Are you eligible?
Gender
Male and female
Age
18 years and older
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.